Anika Therapeutics EPS Ratio 2011-2026 | ANIK

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares^[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio Anika Therapeutics

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-5.64	-1.02	0.29	-1.69	1.93	1.3	2.18	2.22	2.06	2.61	1.46	0.89	0.65

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
2.61	-5.64	0.557

Quarterly EPS Ratio Anika Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-0.16	-0.28	-0.34	-	-2.03	-0.01	-0.31	-	-0.45	-0.19	-0.71	-	-0.29	-0.2	-0.2	-	0.04	0.45	0.2	-1.1	-0.45	-0.54	0.41	0.28	0.65	0.68	0.32	0.54	0.53	0.69	-0.46	0.55	0.47	0.78	0.38	0.56	0.61	0.59	0.46	0.74	0.56	0.52	0.24	0.53	0.42	0.63	1.04	0.47	0.36	0.44	0.23	0.33	0.12	0.28	0.15	0.22	0.23	0.18	0.03

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
1.04	-2.03	0.167

References

Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer	EPS Ratio	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-15.4	-	2.43 %	$ 254 M	Germany
argenx SE ARGX	-7.99	$ 834.06	0.94 %	$ 25 B	Niderland
Ascendis Pharma A/S ASND	-8.28	$ 234.24	-0.3 %	$ 5 B	Danmark
Harmony Biosciences Holdings HRMY	2.76	$ 27.99	4.17 %	$ 1.59 B	USA
ARCA biopharma ABIO	-3.87	-	1052.0 %	$ 415 M	USA
Acasti Pharma ACST	-0.79	-	4.01 %	$ 150 M	Canada
Aptorum Group Limited APM	-0.78	$ 0.81	1.31 %	$ 4.42 M	China
Adverum Biotechnologies ADVM	-6.62	-	-	$ 86.2 M	USA
AgeX Therapeutics AGE	-13.7	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	-24.9	-	-	$ 1.01 B	USA
AIkido Pharma AIKI	-2.38	-	1.93 %	$ 17.4 M	USA
I-Mab IMAB	-7.66	-	-	$ 866 M	China
Akero Therapeutics AKRO	-3.75	-	-	$ 3.67 B	USA
Alterity Therapeutics Limited ATHE	-0.53	$ 3.33	0.79 %	$ 8.01 B	Australia
Biophytis SA BPTS	-0.26	-	-13.47 %	$ 169 M	France
Albireo Pharma ALBO	-1.77	-	-0.23 %	$ 916 M	USA
Allena Pharmaceuticals ALNA	-0.72	-	3.16 %	$ 1.9 M	USA
AlloVir ALVR	-11.7	-	4.14 %	$ 49.1 M	USA
Midatech Pharma plc MTP	-31	-	-18.52 %	$ 27.3 M	Britain
Akouos AKUS	-2.52	-	0.23 %	$ 488 M	USA
Ampio Pharmaceuticals AMPE	-10.7	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	-3.25	-	-	$ 10.1 M	USA
Acorda Therapeutics ACOR	-204	-	-24.86 %	$ 820 K	USA
Acer Therapeutics ACER	-1.66	-	2.71 %	$ 14 M	USA
Aravive ARAV	-2.1	-	-13.39 %	$ 1.45 M	USA
Applied Genetic Technologies Corporation AGTC	-0.36	-	-	$ 26.5 M	USA
Avenue Therapeutics ATXI	-15.8	-	-52.27 %	$ 4.45 M	USA
Atea Pharmaceuticals AVIR	-2	$ 4.66	1.42 %	$ 393 M	USA
Axsome Therapeutics AXSM	-3.68	$ 167.61	-4.09 %	$ 8.34 B	USA
Ayala Pharmaceuticals AYLA	-2.46	-	-	$ 7.46 M	Israel
Atreca BCEL	-2.52	-	-11.76 %	$ 5.79 M	USA
Alpine Immune Sciences ALPN	-1.73	-	-	$ 2.17 B	USA
BioDelivery Sciences International BDSI	0.85	-	-4.8 %	$ 255 M	USA
Aeterna Zentaris AEZS	-0.07	-	5.93 %	$ 314 M	Canada
BeiGene, Ltd. BGNE	-0.47	-	0.49 %	$ 251 B	Cayman-islands
Biogen BIIB	8.83	$ 194.87	-0.75 %	$ 28.5 B	USA
BioVie BIVI	-12.1	$ 1.25	0.4 %	$ 1.85 M	USA
Bellicum Pharmaceuticals BLCM	-0.81	-	-9.72 %	$ 5.89 M	USA
BioMarin Pharmaceutical BMRN	2.25	$ 63.02	0.15 %	$ 12 B	USA
Baudax Bio BXRX	-177	-	0.59 %	$ 63 K	USA
Aptose Biosciences APTO	-36.4	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	-0.96	-	-39.0 %	$ 4.57 M	USA
Aridis Pharmaceuticals ARDS	-1.62	-	17.91 %	$ 11.1 M	USA
BioNTech SE BNTX	42.2	$ 110.88	0.86 %	$ 27.2 B	Germany
Amneal Pharmaceuticals AMRX	-0.38	$ 14.72	2.08 %	$ 4.55 B	USA
Arena Pharmaceuticals ARNA	-10.1	-	-6.81 %	$ 3.04 B	USA